Iron Overload in Allogeneic Hematopoietic Cell Transplantation Outcome: A Meta-Analysis

Biology of Blood and Marrow Transplantation

Volumn 20, Issue 8, 2014, Pages 1248-1251

  Armand, Philippe ^a   Kim, Haesook T ^a   Virtanen, Johanna M ^b   Parkkola, Riitta K ^b   Itälä Remes, Maija A ^b   Majhail, Navneet S ^c   Burns, Linda J ^d   DeFor, Todd ^d   Trottier, Bryan ^d   Platzbecker, Uwe ^e   Antin, Joseph H ^a   Wermke, Martin ^e  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b TURKU UNIVERSITY HOSPITAL   (Finland)

^c LERNER RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^e UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

Allogeneic hematopoietic cell transplantation; Iron overload; Serum ferritin

Indexed keywords

FERRITIN; IRON;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; FERRITIN BLOOD LEVEL; HAZARD RATIO; HUMAN; IRON OVERLOAD; META ANALYSIS; MORTALITY; NONRELAPSE MORTALITY; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PROGNOSIS; ADOLESCENT; ADULT; AGED; BLOOD; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOSUPPRESSIVE TREATMENT; MALE; MIDDLE AGED; PROCEDURES; SURVIVAL; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; FEMALE; FERRITINS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IRON; IRON OVERLOAD; MALE; MIDDLE AGED; PROGNOSIS; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84904065494     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2014.04.024     Document Type: Article

References (31)

1. Alessandrino E.P., Della Porta M.G., Bacigalupo A., et al. Prognostic impact of pre-transplantation transfusion history and secondary iron overload in patients with myelodysplastic syndrome undergoing allogeneic stem cell transplantation: a GITMO study. Haematologica 2010, 95:476-484.
2. Armand P., Kim H.T., Cutler C.S., et al. Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood 2007, 109:4586-4588.
3. Armand P., Sainvil M.M., Kim H.T., et al. Does iron overload really matter in stem cell transplantation?. Am J Hematol 2012, 87:569-572.
4. Bazuave G.N., Buser A., Gerull S., et al. Prognostic impact of iron parameters in patients undergoing allo-SCT. Bone Marrow Transplant 2012, 47:60-64.
5. Kataoka K., Nannya Y., Hangaishi A., et al. Influence of pretransplantation serum ferritin on nonrelapse mortality after myeloablative and nonmyeloablative allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2009, 15:195-204.
6. Kim Y.R., Kim J.S., Cheong J.W., et al. Transfusion-associated iron overload as an adverse risk factor for transplantation outcome in patients undergoing reduced-intensity stem cell transplantation for myeloid malignancies. Acta Haematol 2008, 120:182-189.
7. Lim Z.Y., Fiaccadori V., Gandhi S., et al. Impact of pre-transplant serum ferritin on outcomes of patients with myelodysplastic syndromes or secondary acute myeloid leukaemia receiving reduced intensity conditioning allogeneic haematopoietic stem cell transplantation. Leuk Res 2009, 34:723-727.
8. Mahindra A., Bolwell B., Sobecks R., et al. Elevated pretransplant ferritin is associated with a lower incidence of chronic graft-versus-host disease and inferior survival after myeloablative allogeneic haematopoietic stem cell transplantation. Br J Haematol 2009, 146:310-316.
9. Platzbecker U., Bornhauser M., Germing U., et al. Red blood cell transfusion dependence and outcome after allogeneic peripheral blood stem cell transplantation in patients with de novo myelodysplastic syndrome (MDS). Biol Blood Marrow Transplant 2008, 14:1217-1225.
10. Pullarkat V., Blanchard S., Tegtmeier B., et al. Iron overload adversely affects outcome of allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2008, 42:799-805.
11. Sucak G.T., Yegin Z.A., Ozkurt Z.N., et al. Iron overload: predictor of adverse outcome in hematopoietic stem cell transplantation. Transplant Proc 2010, 42:1841-1848.
12. Trottier B.J., Burns L.J., Defor T.E., et al. Association of iron overload with allogeneic hematopoietic cell transplantation outcomes: a prospective cohort study using R2-MRI-measured liver iron content. Blood 2013, 122:1678-1684.
13. Wermke M., Schmidt A., Middeke J.M., et al. MRI-based liver iron contentpredicts for nonrelapse mortality in MDS and AML patients undergoing allogeneic stem cell transplantation. Clin Cancer Res 2012, 18:6460-6468.
14. Meyer S.C., O'Meara A., Buser A.S., et al. Prognostic impact of posttransplantation iron overload after allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2013, 19:440-444.
15. Grossekatthofer M., Guclu E.D., Lawitschka A., et al. Ferritin concentrations correlate to outcome of hematopoietic stem cell transplantation but do not serve as biomarker of graft-versus-host disease. Ann Hematol 2013, 92:1121-1128.
16. Gandon Y., Olivie D., Guyader D., et al. Non-invasive assessment of hepatic iron stores by MRI. Lancet 2004, 363:357-362.
17. St Pierre T.G., Clark P.R., Chua-anusorn W., et al. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood 2005, 105:855-861.
18. Armand P., Kim H.T., Rhodes J., et al. Iron overload in patients with acute leukemia or MDS undergoing myeloablative stem cell transplantation. Biol Blood Marrow Transplant 2011, 17:852-860.
19. Brittenham G.M., Griffith P.M., Nienhuis A.W., et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. NEngl J Med 1994, 331:567-573.
20. Vag T., Kentouche K., Krumbein I., et al. Noninvasive measurement of liver iron concentration at MRI in children with acute leukemia: initial results. Pediatr Radiol 2011, 41:980-984.
21. Olivieri N.F., Brittenham G.M., Matsui D., et al. Iron-chelation therapy with oral deferipronein patients with thalassemia major. NEngl J Med 1995, 332:918-922.
22. Virtanen J.M., Itala-Remes M.A., Remes K.J., et al. Prognostic impact of pretransplant iron overload measured with magnetic resonance imaging on severe infections in allogeneic stem cell transplantation. Eur J Haematol 2013, 91:85-93.
23. Fine J., Gray R. Aproportional hazards model for the subdistribution of a competing risk. JAm Statistical Assoc 1999, 94:496-509.
24. DerSimonian R., Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986, 7:177-188.
25. Higgins J.P., Thompson S.G. Quantifying heterogeneity in a meta-analysis. Stat Med 2002, 21:1539-1558.
26. Armand P., Sainvil M.M., Kim H.T., et al. Pre-transplantation iron chelation in patients with MDS or acute leukemia and iron overload undergoing myeloablative allo-SCT. Bone Marrow Transplant 2013, 48:146-147.
27. Kaloyannidis P., Yannaki E., Sakellari I., et al. The impact of desferrioxamine postallogeneic hematopoietic cell transplantation in relapse incidence and disease-free survival: a retrospective analysis. Transplantation 2010, 89:472-479.
28. Majhail N.S., Lazarus H.M., Burns L.J. Aprospective study of iron overload management in allogeneic hematopoietic cell transplantation survivors. Biol Blood Marrow Transplant 2010, 16:832-837.
29. Sivgin S., Baldane S., Akyol G., et al. The oral iron chelator deferasirox might improve survival in allogeneic hematopoietic cell transplant (alloHSCT) recipients with transfusional iron overload. Transfus Apher Sci 2013, 49:295-301.
30. Sivgin S., Eser B., Bahcebasi S., et al. Efficacy and safety of oral deferasirox treatment in the posttransplant period for patients who have undergone allogeneic hematopoietic stem cell transplantation (alloHSCT). Ann Hematol 2012, 91:743-749.
31. Alessandrino E.P., Angelucci E., Cazzola M., et al. Iron overload and iron chelation therapy in patients with myelodysplastic syndrome treated by allogeneic stem-cell transplantation: report from the working conference on iron chelation of the Gruppo Italiano Trapianto di Midollo Osseo. Am J Hematol 2011, 86:897-902.